Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing.


Journal

Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 25 03 2019
accepted: 23 04 2019
pubmed: 3 5 2019
medline: 26 11 2019
entrez: 4 5 2019
Statut: ppublish

Résumé

The colorectal cancer harbor germline, somatic or epimutations in mismatch repair genes, MUTYH or POLE gene, which lead to the hypermutated and ultramutator phenotypes with increased immune response. The mutations in POLE gene were reported to occur more frequently in early-onset colorectal cancer (EOCRC), and the patients are strong candidates for checkpoint inhibitor therapy. Here, we report mutation analysis within the endonuclease domain of the POLE gene in the cohort of patients with EOCRC in order to identify recurrent or new mutations and evaluate their association with the presence of tumor-infiltrating lymphocytes (TILs) and peritumoral lymphoid reaction. We have shown a significant association between MSI tumors and TILs (p = 0.004). Using sensitive single-tube nested PCR with subsequent Sanger sequencing, we have found in one female patient diagnosed at age 48 with rectal adenocarcinoma with mucinous elements staged pT3pN2pM1 a silent variant within the exon 9 NM_006231.3 c.849 C > T, NP_00622.2 p.Leu283 = recorded in dSNP as rs1232888774 with MAF = 0.00002. In silico prediction, result showed possible involvement into splicing; therefore, this rare variant can be involved into EOCRC pathogenesis. In the time of precise medicine, it is important to develop screening strategies also for less common conditions such as EOCRC allowing to predict tailored therapy for younger patients suffering from CRC that harbor mutations in the POLE gene.

Identifiants

pubmed: 31049795
doi: 10.1007/s10238-019-00558-7
pii: 10.1007/s10238-019-00558-7
doi:

Substances chimiques

Poly-ADP-Ribose Binding Proteins 0
DNA Polymerase II EC 2.7.7.7
POLE protein, human EC 2.7.7.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-400

Subventions

Organisme : Agentúra Ministerstva Školstva, Vedy, Výskumu a Športu SR
ID : 1/0380/18
Organisme : Agentúra Ministerstva Školstva, Vedy, Výskumu a Športu SR
ID : 1/0199/17
Organisme : Russian Science Support Foundation (RU)
ID : Grant 08-08

Références

Gastroenterology. 2007 Jul;133(1):48-56
pubmed: 17631130
Am J Surg Pathol. 2010 Dec;34(12):1820-9
pubmed: 21107088
Int J Colorectal Dis. 2012 Jan;27(1):71-9
pubmed: 21881876
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
Hum Mol Genet. 2013 Jul 15;22(14):2820-8
pubmed: 23528559
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Genet Med. 2016 Apr;18(4):325-32
pubmed: 26133394
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
Nat Rev Cancer. 2016 Feb;16(2):71-81
pubmed: 26822575
Oncotarget. 2016 Oct 18;7(42):68638-68649
pubmed: 27612425
Virchows Arch. 2017 Jan;470(1):29-36
pubmed: 27864688
J Pathol. 2017 May;242(1):10-15
pubmed: 28127763
J Natl Compr Canc Netw. 2017 Feb;15(2):142-147
pubmed: 28188185
Curr Treat Options Oncol. 2017 Apr;18(4):23
pubmed: 28391421
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216
pubmed: 28404093
Oncotarget. 2017 Apr 18;8(16):26732-26743
pubmed: 28423643
Exp Mol Pathol. 2017 Jun;102(3):475-483
pubmed: 28506769
Cancer Med. 2017 Dec;6(12):2966-2971
pubmed: 29072370
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
Lung Cancer. 2018 Apr;118:57-61
pubmed: 29572003
J Pathol. 2018 Jul;245(3):283-296
pubmed: 29604063
PLoS Med. 2018 Jun 1;15(6):e1002577
pubmed: 29856736
J Gastrointest Oncol. 2018 Jun;9(3):404-415
pubmed: 29998005
J Gastrointest Oncol. 2018 Aug;9(4):E23-E27
pubmed: 30151276
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Transl Res. 2018 Nov 15;10(11):3773-3781
pubmed: 30662627
Oncol Lett. 2019 Apr;17(4):3649-3656
pubmed: 30881489

Auteurs

Zora Lasabová (Z)

Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Maláhora 4C, 03601, Martin, Slovakia. lasabova@jfmed.uniba.sk.
Department of Molecular Biology and Genomics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. lasabova@jfmed.uniba.sk.

Michal Kalman (M)

Department of Pathological Anatomy, Jessenius Faculty of Medicine University Hospital in Martin, Comenius University in Bratislava, Martin, Slovakia.

Veronika Holubeková (V)

Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Maláhora 4C, 03601, Martin, Slovakia.

Marián Grendár (M)

Department of Bioinformatics, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.

Ivana Kašubová (I)

Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Maláhora 4C, 03601, Martin, Slovakia.

Karin Jašek (K)

Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Maláhora 4C, 03601, Martin, Slovakia.

Sandra Meršaková (S)

Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Maláhora 4C, 03601, Martin, Slovakia.

Bibiana Malicherová (B)

Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Maláhora 4C, 03601, Martin, Slovakia.

Denis Baranenko (D)

International Research Centre "Biotechnologies of the Third Millennium", ITMO University, Saint-Petersburg, Russian Federation.

Mariusz Adamek (M)

Department of Thoracic Surgery, Faculty of Medicine and Dentistry, Medical University of Silesia, Katowice, Poland.

Peter Kruzliak (P)

Department of Internal Medicine, Brothers of Mercy Hospital, Brno, Czech Republic. kruzliakpeter@gmail.com.

Lukáš Plank (L)

Department of Pathological Anatomy, Jessenius Faculty of Medicine University Hospital in Martin, Comenius University in Bratislava, Martin, Slovakia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH